PPAR-α agonists are still on the rise: an update on clinical and experimental findings (Q39200940)

9 September 2017

PPAR-α agonists are still on the rise: an update on clinical and experimental findings (English)

1 reference

9 September 2017

Nicola Ferri

1

1 reference

9 September 2017

Alberto Corsini

series ordinal

2

1 reference

9 September 2017

Cesare Sirtori

series ordinal

3

1 reference

9 September 2017

Massimiliano Ruscica

series ordinal

4

1 reference

9 September 2017

language of work or name

English

0 references

publication date

27 March 2017

1 reference

Expert Opinion on Investigational Drugs

9 September 2017

1 reference

9 September 2017

26

1 reference

9 September 2017

593-602

1 reference

9 September 2017

5

1 reference

Interpretation of the evidence for the efficacy and safety of statin therapy

9 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Triglycerides and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Insulin resistance and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Update on the use of fibrates: focus on bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

The roles of peroxisome proliferator-activated receptors in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Combination lipid therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Do persons with diabetes benefit from combination statin and fibrate therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Evaluating bempedoic acid for the treatment of hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

The future of n-3 polyunsaturated fatty acid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Regulation of apo A-I gene expression by fibrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

On the mechanism for PPAR agonists to enhance ABCA1 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Effects of the PPARα agonist WY-14,643 on plasma lipids, enzymatic activities and mRNA expression of lipid metabolism genes in a marine flatfish, Scophthalmus maximus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

WY14643 combined with all-trans retinoic acid acts via p38 MAPK to induce "browning" of white adipocytes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

The impact of PPARα activation on whole genome gene expression in human precision cut liver slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Impact of PPAR-α induction on glucose homoeostasis in alcohol-fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Safety considerations with fenofibrate/simvastatin combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Fibrates: what have we learned in the past 40 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Risk identification and possible countermeasures for muscle adverse effects during statin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

The role of mitochondria in statin-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Browning of White Fat: Novel Insight Into Factors, Mechanisms, and Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Adipose tissue in control of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Remnant cholesterol as a causal risk factor for ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1312339

10.1080/13543784.2017.1312339

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference